Lucid Diagnostics Announces Closing of Nasdaq Initial Public Offering
18 oct. 2021 17h45 HE
|
Lucid Diagnostics Inc.
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
07 oct. 2021 11h41 HE
|
PAVmed Inc.
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical technology company, today...
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
10 juin 2021 09h30 HE
|
PAVmed Inc.
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that its...